T he continuous growth of tumors depends on altered regulation of the cell cycle, modulated by signal transduction and mediated by growth factors and their receptors. 1 Among these are the insulin -like growth factors ( IGFs ), peptides of about 7500 Da that can stimulate cellular proliferation and induce cellular differentiation.
The roles of IGF -I and IGF -IR in cancer cells have been investigated extensively. In certain systems, the IGF -IR appears to be essential for malignant transformation, maintenance of the malignant phenotype, and also inhibition of apoptotic responses. 2 -4 Blockade of IGF -IR by antisense, 5, 6 dominant negative plasmid transfection, 7 -11 or triple helix formation 12 has been shown to suppress tumor formation and induce regression of established tumors.
Stable introduction of antisense, dominant negative plasmids or the use of antisense oligonucleotides presents a variety of obstacles for practical cancer gene therapy strategies. Adenoviruses represent excellent vectors for the introduction of IGF -IR dominant negative constructs into tumors for many reasons. Adenoviruses are highly infective for the actively dividing, slowly dividing, and nondividing tumor cells that often coexist in solid tumors, and they express high levels of the transduced gene. 13, 14 We have already published a study in which we constructed an adenovirus expressing an antisense IGF -IR driven by a CMV promoter, and found it to be effective in the reduction of IGF -I binding and in the therapy of a human lung cancer xenograft model. 15 IGF -IR is synthesized as a single precursor peptide of 1367 amino acid residues, with a structure consisting of three domains: an NH 2 signal peptide, the a subunit, and a Cterminal b subunit. The cleavage of the signal peptide results in a 1337 -amino-acid proreceptor. This proreceptor is then cleaved at residue 706, into a and b subunits. The a subunit of 706 -amino-acid residues, required for ligand binding, is entirely extracellular and forms a dimer with another a subunit in the active form of the receptor. The b subunit has an extracellular, a transmembrane, and an intracellular region. The intracellular portion of b subunit has a binding site for IRS and Shc (Y950 ). The tyrosine cluster at 1131, 1135, and 1136 is within the tyrosine kinase domain. 4 In this study, we have constructed two recombinant adenoviruses for dominant negative inhibition of IGF -IR. The first is an adenovirus expressing IGF -IR with an engineered stop codon at amino acid residue 950 (ad -IGF -IR /950 ). This produces a defective, truncated receptor on the cell surface (intact a subunit and defective b subunit lacking the tyrosine kinase domain). This molecule has the ability to form inactive heterodimers with wild -type receptor monomers. The second is an adenovirus expressing IGF -IR with an engineered stop codon at amino acid residue 482 ( ad-IGF -IR /482 ). This produces a soluble fragment of the a subunit of IGF -IR that should compete for ligand in the extracellular environment. We found that both ad -IGF -IR/ 950 and ad -IGF -IR/ 482 block IGF -I signaling and show antitumor effects on lung cancer cell lines, and that the soluble receptor was significantly more effective than the transmembrane version in preclinical models of human lung cancer.
Materials and methods

Cell lines, tissue culture, and animals
Lung cancer cell lines ( A549: human bronchioloalveolar cell carcinoma, and NCI H460: human large cell carcinoma ) were purchased from the ATCC ( Manassas, VA ) and KCLB ( Seoul, South Korea). Cells were grown in RPMI 1640 supplemented with 8% FBS and 100 U of penicillin and streptomycin. IGF -I and antibody to IGF -1R (a -IR3 ) were purchased from Amersham Pharmacia Biotechnologies (Buckinghamshire, UK ) and Oncogene Science ( Cambridge, MA ), respectively. Balb /C nude mice (female, 4 weeks old ) were purchased from SLC (Hamamatsu, Japan ).
Construction of adenoviruses expressing dominant negative IGF -IRs ( 950STOP / 482STOP ) ( ad -IGF -IR / 950, ad -IGF -IR / 482 )
The cDNA of IGF -IR ( 950STOP and 482STOP ) were generated by RT-PCR from mRNA of NCI H460 with designed primers for the insertion of stop codon at 950 [ TAC( Tyr ) to TAA( STOP)] or at 482 [ TAC( Tyr ) to TAA( STOP) ]. Both ends of these cDNA were engineered to contain EcoRI restriction sites. After digestion with EcoRI, these cDNA segments were cloned into the EcoRI restriction site of the pUC19 polylinker in the vector pAC CMVpLpA (a gift of Robert D Gerard, University of Texas Southwestern Medical Center, Dallas, TX ). After the confirmation by automatic DNA sequencing (ABI 373 sequencer; Perkin -Elmer, Norwalk, CT ), pAC CMV-IGF -IR /950STOP or pAC CMV-IGF -IR / 482STOP and pJM17 were cotransfected into 293 cells by standard calcium phosphate precipitation methods. Ad -IGF -IR / 950 and ad-IGF -IR /482 were generated by homologous recombination in 293 cells. 16 The resulting adenoviruses were purified by plaque assay and confirmed again by sequencing of the viral DNA. For the described experiments, adenovirus lacZ was used as a control virus. . After 48 hours, the media were replaced by serum -free medium. Twenty -four hours later, 50 ng /mL IGF -I was added to the medium containing 0.5 mg /mL BSA and incubated for 16 hours more. Cells were then pulsed with 1 mCi of [ 3 H ]thymidine for 6 hours. After washing with medium, cells were precipitated with 10% TCA for 30 minutes on ice, and solubilized by in 0.1 M NaOH, and the incorporated radioactivity was measured. Stimulation indices were calculated by the ratio of [ (incorporated radioactivity with IGF -IÀ incorporated radioactivity without IGF -I )/ incorporated radioactivity without IGF -I ]. 17 
Soft agar clonogenic assay
Anchorage -independent growth as a parameter of in vitro tumorigenicity was assessed by soft agar clonogenic assay. Brief ly, the human lung cancer cell line (NCI H460 ) was transduced with ad -IGF -IR /950 or ad-IGF -IR/ 482 ( 30 MOI). After incubation for 48 hours, cells were detached and plated in 0.2% agarose with a 1% agarose underlay (5Â10 3 / well in six -well plates). Colonies greater than 125 m were counted using a calibrated scale. 15 
Treatment of human lung cancer xenografts with intratumoral injection of ad -IGF -IR / 950 and ad -IGF -IR / 482
Treatment potentials of ad -IGF -IR /950 and ad -IGF -IR / 482 were measured by intratumoral injection into established lung cancer xenografts. To simulate real clinical situations, we generated relatively large tumors of 350 -400 mm 3 by injecting 2Â10 6 cells of NCI H460 into subcutaneous tissue of nude mice (five mice in each group ) and waiting for 2 weeks. Intratumoral injections of adenoviruses (1.0Â10 9 pfu /day ) were done for five consecutive days. Tumor sizes were calculated by the formula: volume= 1 / 2(width ) 2 Âlength. The statistical significance of differences in tumor volumes was determined by SPSS, general linear mode, repeated measure form.
Results
Transduction with ad -IGF -IR / 950 increased the surface expression of IGF -IR
FACS confirmed that transduction with ad -IGF -IR /950 induced the significant increase in IGF -IR on two human lung cancer cell lines ( A549, NCI H460 ). Higher doses ( MOI ) of adenovirus induced higher expression of IGF -IR. Because the monoclonal antibody used for the staining was specific for the a subunit, it could not discriminate the normal and defective IGF -IR. Transduction with ad -IGF -IR /482 failed to show any significant change in IGF -IR numbers because this virus produces a defective a subunit without transmembrane and intracellular portions, and this fragment is not predicted to be retained on the cell surface, except when complexed with intact receptor molecules (Fig 1 ) . (Fig 3) . Even though both adenoviruses could block activation, ad-IGF -IR/ 950 was more effective in blocking Akt kinase activation. These data showed that defective IGF -IR presentation or soluble inhibitor expression by ad-IGF -IR /dn could block known IGF -I signaling pathways effectively. 
Decreased colony formation of lung cancer cells transduced with ad -IGF -IR / 950 and ad -IGF -IR / 482
We showed previously that reduction of IGF -IR number by an IGF -IR antisense -expressing adenovirus induced marked suppression of colony formation in a soft agar clonogenic assay. 15 Both defective receptors expressed on ad -IGF -IR / 950-transduced cells and soluble inhibitors produced by ad -IGF -IR /482 -transduced cells also induced marked suppression of colony formation in a soft agar clonogenic assay ( untransduced: 428 ± 26; ad -lacZ: 307 ± 24; ad -IGF -IR / 950: 28 ± 7; ad -IGF -IR /482: 45± 3 ) ( Fig 5) . This finding also suggested the induction of competitive inhibition by 
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Growth suppression of lung cancer xenografts by intratumoral injection of ad -IGF -IR / 482
Intratumoral injection of ad -IGF -IR /482 into tumors induced very strong growth suppression with initial regression. However, ad -IGF -IR /950 injection failed to show significant suppression of tumor growth ( Fig 6) . In Akt kinase inhibition, [ 3 H ]thymidine incorporation assay, and soft agar clonogenic assays, ad -IGF -IR /950 showed more potent effect in blocking IGF -I action; however, ad-IGF -IR /482 showed more potent growth suppression than ad-IGF -IR /950 (P < .01) ( Figs 6 and 7d) . We can explain this phenomenon by virtue of the fact that intratumoral injection of adenovirus transduces only a small portion of the tumor cells, in contrast to the much higher transduction efficiencies observed in in vitro monolayer culture experiments. Thus, the bystander effect of the soluble receptor fragment produced by ad -IGF -IR/ 482-transduced cells could result in the more potent growthinhibitory effect of this virus when directly injected into solid tumors.
Discussion
The importance of IGF -I and IGF -IR in cancer has been confirmed by many lines of evidence. Several case -control studies have shown the association of elevated serum IGF -I level with increased risk for prostate cancer, 20 colorectal cancer, 21 and lung cancer. 22 Therapeutic manipulations to block IGF -I signal transduction have profound antitumor effects in many systems. IGF -1 signaling may be blocked using monoclonal antibodies, genetic blockade ( as used here ) to reduce the expression or inactivate the receptor, and agents that directly block the receptor tyrosine kinase activity.
As an example of the first strategy, a -IR3, a monoclonal antibody to IGF -IR, significantly inhibited Ewing sarcoma cells in vitro and induced the regression of established tumors. 23 Similar studies have shown inhibition of lung cancer cell line growth. Genetic blockade can be accomplished using antisense strategies to inhibit expression of IGF -I or IGF -IR. Antisense oligonucleotide or plasmid transfection expressing antisense IGF -I 24 or IGF -IR 5,6 has shown activity. We have shown that an adenovirus expressing antisense IGF -IR decreased IGF -IR receptor expression and had therapeutic effects on established human lung cancer xenografts. 15 Another genetic strategy to block IGF -I Figure 7 Gross appearance of representative tumors in each group of mice. This was taken on day 14 after the start of adenovirus injection. 
Cancer Gene Therapy
Adenoviruses -IGF -IR/dn demonstrate antitumor effects on lung cancer C -T Lee et al signaling is through expression of a dominant negative mutated or truncated IGF -IR. Prager et al 7 reported that stable transfection of a truncated b subunit of IGF -IR ( 952STOP) inhibited the tumorigenicity of rat tumor cell line by dominant negative inhibition. Miura et al 8 showed that the mouse embryo fibroblasts (R -cells ) transfected with IGF -I receptor of mutated Y950F had lost its ability to transmit an IGF -I-mediated mitogenic signal or to transform to R -cells. Stable expression of myristoylated COOH terminus of IGF -IR inhibited tumorigenesis and induced apoptosis in human ovarian and glioblastoma cells. 25 Dunn et al 11 reported that impairment of IGF -IR function was also effectively achieved by transfecting a form of IGF -IR truncated at codon 486. IGF -IR 486STOP was found to be secreted extracellularly, resulting in a strong bystander effect, with inhibition of adhesion, invasion, and metastasis in a breast cancer model. Reiss et al 10 also demonstrated that the 486STOP mutant of IGF -IR inhibited tumor formation and showed a bystander effect.
Previous dominant negative strategies of IGF -IR have used stable plasmid transfection that is impractically inefficient in clinical situations. To facilitate the application of dominant negative blockade of IGF -IR in clinical practice, we have constructed two recombinant adenoviruses expressing dominant negative IGF -IR by insertion of stop codons at 950 or 482. A single transduction of ad -IGF -IR/ 950 induced increased expression of IGF -IR that was virus dose -dependent. Using the monoclonal antibody a-IR3 ( specific for initial portion of a subunit of IGF -IR, so it detects both normal an dominant negative receptors ), we found a marked increase in receptor number after the transduction. Most of the receptors detected in FACS would be expected to be the normal /truncated heterodimer or truncated /truncated dimer of IGF -IR. After transduction by this virus, blunted DNA synthesis by IGF -I in lung cancer cells was observed. However, transduction with ad -IGF -IR/ 482 did not change the expression of IGF -IR on the cell surface as detected by this antibody because mutant monomers and homodimers would lack membrane -anchoring sequences. Western blot assay of conditioned media after transduction revealed that ad-IGF -IR /482 induced the release of this IGF -IR fragment extracellularly as a soluble inhibitor. This secretion into the medium is the basis of the bystander effect of ad -IGF -IR /482 observed with this virus. We have also shown the presence of a bystander effect using our tetracycline -regulated plasmid vector encoding IGF -IR/ 482 (Adachi et al, in preparation ).
Multiple signaling pathways are involved in the antiapoptotic activity of IGF -IR and its ligand. The main signaling pathway for IGF -IR -mediated effects on apoptosis is mediated through the activation of phosphatidylinositol 3-kinase, Akt / protein kinase B, and phosphorylation of BAD. Other alternative pathways of IGF -IR effects on apoptosis are the activation of mitogen -activated protein kinase ( MAPK ) and mitochondrial translocation of Raf. These two pathways also result in BAD phosphorylation. [26] [27] [28] [29] When Akt is activated by IGF -IR and its ligand, it phosphorylates the proapoptotic Bcl -2 family member BAD at serines 112 and 136. Phosphorylated BAD loses its ability to form a heterodimer with Bcl -X L at membrane sites, is sequestered in the cytoplasm with 14.3.3, and finally loses its proapoptotic characteristics. 26 Thus, blocking of Akt phosphorylation leads to apoptosis.
Studies with point mutant IGF -IR reveal that tyrosine residues at 950, 1131, 1135, and 1136 of IGF -IR are necessary for Akt phosphorylation and subsequent apoptosis. 29 In this report, transduction with ad-IGF -IR /950 and ad -IGF -IR /482 that express defective IGF -IRs, deleted for the region containing these tyrosine residues, effectively blocked IGF -I-induced Akt kinase activation. Ad -IGF -IR / 950 almost completely inhibited Akt kinase activation, and appeared to do so more effectively than ad -IGF -IR /482, perhaps due to the fact that heterodimers containing the transmembrane receptor fragment and wild type were more stable or better retained in the membrane.
Blockade of IGF -I signaling was also demonstrated in these studies by an effective block of IGF -I-induced DNA synthesis, an index of mitogenesis that is another characteristic of IGF -IR. Transduction with these adenoviruses effectively blunted IGF -I-induced DNA synthesis. Both ad-IGF -IR /950 and ad -IGF -IR /482 induced a marked decrease in in vitro tumorigenicity of lung cancer cell lines in soft agar clonogenic assays.
In all in vitro experiments, ad -IGF -IR /950 appeared to be more effective than ad -IGF -IR /482 in blocking IGF -IR function. However, in in vivo treatment models, ad -IGF -IR / 482 showed more powerful growth inhibition of established lung cancer xenograft tumors than ad-IGF -IR/ 950. We explained this discrepancy by virtue of the low transduction efficiency resulting from intratumoral injection. Whereas ad-IGF -IR /950 can exert its inhibitory effect only in transduced cells, ad-IGF -IR /482-transduced cells produce a soluble inhibitor that can block IGF -I signaling of neighboring cells ( a bystander effect). This bystander effect has been previously confirmed after stable transfection of dominant negative IGF -IR with stop codon at 486. 10 Furthermore, tumor cells stably transfected with the IGF -IR with a stop codon at 482 showed massive apoptosis when injected into animals. 30 Another in vivo tumorigenicity experiment with A549 (human bronchioloalveolar cell carcinoma ) stably transfected by dominant negative IGF -IR ( 952STOP) showed decreased tumorigenicity with glandular differentiation without evidence of apoptosis. 31 Previous experiments of IGF -IR blockade in immunocompetent animals showed that blockade of IGF -I signaling induced potent antitumor immune responses that caused regression of untreated tumors. 5, 6 In our nude mouse xenograft model, we clearly would not expect the induction of immune responses. However, if we applied these therapeutic viruses in syngeneic tumor models in immunocompetent animals ( or against human tumors ), these adenoviruses may demonstrate even more potent antitumor effects.
In conclusion, ad -IGF -IR /dn can block the mitogenic, antiapoptotic, and tumorigenic activities of IGF -IR effectively, both in vitro and in vivo, including induction of growth suppression of established tumors.
These findings suggest that these adenoviruses expressing dominant negative IGF -IR could be an effective new strategy for cancer gene therapy and a useful tool for IGF -IR functional assays.
